U.S. Markets open in 5 mins.

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
167.29-0.52 (-0.31%)
At close: 4:00PM EDT

167.50 +0.21 (0.13%)
Pre-Market: 8:17AM EDT

People also watch
BIIBGILDCELGMRKBMY

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320
United States
805-447-1000
http://www.amgen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees19,200

Key Executives

NameTitlePayExercisedAge
Mr. Robert A. BradwayChairman and Chief Exec. Officer5.85M8.19M54
Mr. David W. MelineChief Financial Officer and Exec. VP2.72MN/A60
Mr. Jonathan P. GrahamSr. VP, Gen. Counsel and Sec.4.12MN/A56
Dr. Sean E. Harper M.D.Exec. VP of R&D2.71MN/A54
Mr. Anthony C. HooperExec. VP of Global Commercial Operations2.97MN/A62
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company’s other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; Array BioPharma Inc.; and Syngene International Limited. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Corporate Governance

Amgen Inc.’s ISS Governance QualityScore as of August 1, 2017 is 1. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.